Literature DB >> 12717221

CD103 mRNA levels in urinary cells predict acute rejection of renal allografts.

Ruchuang Ding1, Baogui Li, Thangamani Muthukumar, Darshana Dadhania, Mara Medeiros, Choli Hartono, David Serur, Surya V Seshan, Vijay K Sharma, Sandip Kapur, Manikkam Suthanthiran.   

Abstract

BACKGROUND: CD103 is displayed on the cell surface of alloreactive CD8 cytotoxic T lymphocytes (CTLs) and is a critical component for the intraepithelial homing of T cells. Because intratubular localization of mononuclear cells is a feature of acute cellular rejection of renal allografts, we explored the hypothesis that CD103 messenger (m)RNA levels in urinary cells predict acute rejection.
METHODS: We collected 89 urine specimens from 79 recipients of renal allografts. RNA was isolated from the urinary cells, and we measured CD103 mRNA levels and a constitutively expressed 18S ribosomal (r)RNA with the use of real-time quantitative polymerase chain reaction assay.
RESULTS: CD103 mRNA levels, but not 18S rRNA levels, were higher in urinary cells from 30 patients with an episode of acute rejection (32 biopsies and 32 urine samples) compared with the levels in 12 patients with other findings on allograft biopsy (12 biopsies and 12 urine samples), 12 patients with biopsy evidence of chronic allograft nephropathy (12 biopsies and 12 urine samples), and 25 patients with stable graft function after renal transplantation (0 biopsies and 33 urine samples) (P = 0.001; one-way analysis of variance). Acute rejection was predicted with a sensitivity of 59% and a specificity of 75% using natural log-transformed value 8.16 CD103 copies per microgram as the cutoff value (P = 0.001).
CONCLUSION: CD103 mRNA levels in urinary cells are diagnostic of acute rejection of renal allografts. Because CD103 is a cell surface marker of intratubular CD8 CTLs, a noninvasive assessment of cellular traffic into the allograft may be feasible by the measurement of CD103 mRNA levels in urinary cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12717221     DOI: 10.1097/01.TP.0000064210.92444.B5

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  33 in total

Review 1.  The Immune Tolerance Network at 10 years: tolerance research at the bedside.

Authors:  Jeffrey A Bluestone; Hugh Auchincloss; Gerald T Nepom; Daniel Rotrosen; E William St Clair; Laurence A Turka
Journal:  Nat Rev Immunol       Date:  2010-11       Impact factor: 53.106

Review 2.  Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs.

Authors:  Alberto Sánchez-Fueyo; Terry B Strom
Journal:  Gastroenterology       Date:  2010-11-09       Impact factor: 22.682

3.  Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts.

Authors:  Maria Koulmanda; Ejona Budo; Susan Bonner-Weir; Andi Qipo; Prabhakar Putheti; Nicolas Degauque; Hang Shi; Zhigang Fan; Jeffrey S Flier; Hugh Auchincloss; Xin Xiao Zheng; Terry B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-01       Impact factor: 11.205

Review 4.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

Review 5.  Renal transplant rejection markers.

Authors:  Wilfried Gwinner
Journal:  World J Urol       Date:  2007-09-05       Impact factor: 4.226

Review 6.  Detecting adaptive immunity: applications in transplantation monitoring.

Authors:  Georg A Böhmig; Markus Wahrmann; Marcus D Säemann
Journal:  Mol Diagn Ther       Date:  2010-02-01       Impact factor: 4.074

Review 7.  Biomarkers to detect rejection after kidney transplantation.

Authors:  Vikas R Dharnidharka; Andrew Malone
Journal:  Pediatr Nephrol       Date:  2017-06-19       Impact factor: 3.714

Review 8.  Immune monitoring as prerequisite for transplantation tolerance trials.

Authors:  K Behnam Sani; B Sawitzki
Journal:  Clin Exp Immunol       Date:  2017-06-23       Impact factor: 4.330

Review 9.  Programmed T cell differentiation: Implications for transplantation.

Authors:  Rebecca L Crepeau; Mandy L Ford
Journal:  Cell Immunol       Date:  2020-03-29       Impact factor: 4.868

10.  Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice.

Authors:  Maria Koulmanda; Manoj Bhasin; Lauren Hoffman; Zhigang Fan; Andi Qipo; Hang Shi; Susan Bonner-Weir; Prabhakar Putheti; Nicolas Degauque; Towia A Libermann; Hugh Auchincloss; Jeffrey S Flier; Terry B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.